Current review and clinical management of patients with primary HIV-1 infection: limits and perspectives (Q34322581)

1 August 2017

1 reference

title

Current review and clinical management of patients with primary HIV-1 infection: limits and perspectives (English)

1 reference

1 August 2017

Hermans P

1 reference

1 August 2017

publication date

1 July 2001

1 reference

Biomedicine and Pharmacotherapy

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

301-307

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

A controlled trial of zidovudine in primary human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Primary HIV infection: Follow-up of patients initially randomized to zidovudine or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Early treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Antiretroviral resistance during successful therapy of HIV type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Primary infection with zidovudine-resistant HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

Baseline HIV Type 1 Genotypic Resistance to a Newly Added Nucleoside Analog Is Predictive of Virologic Failure of the New Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2801%2900064-6

7 January 2021

10.1016/S0753-3322(01)00064-6

Identifiers

DOI

1 reference

1 August 2017

1 reference